DRI12544 (18+ years), QUEST (12+ years), VENTURE (12+ years), VOYAGE (6-11 years)

Subjects enrolled in DRI12544 and QUEST were required to have a history of at least 1 severe asthma exacerbation in the year prior to trial entry. A severe asthma exacerbation was defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or asthma-related hospitalization or emergency department visit requiring systemic corticosteroids.1

Subjects enrolled in DRI12544 and QUEST were receiving the SOC for their moderate-to-severe asthma. Those enrolled in VENTURE required dependence on daily OCS in addition to regular use of high-dose ICS plus a minimum of 1 and up to 2 additional controller medications as SOC for their asthma. In all 3 trials, enrollment was unrestricted by minimum baseline blood eosinophil count. In QUEST and VENTURE, subjects with baseline blood eosinophil levels >1500 cells/μL (<1.3%) were excluded.1,13

Subjects enrolled in VOYAGE were children (6-11 years) with uncontrolled moderate-to-severe asthma on an SOC of medium-dose ICS with a second controller medication or high-dose ICS with or without a second controller medication. Subjects were evaluated in 2 prespecified populations: blood EOS ≥300 cells/μL and blood EOS ≥150 cells/μL or FeNO ≥20 ppb (eosinophilic phenotype).9